Aleix Prat

Sobre mi

Publicacions destacades

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

  Autors:

  Villacampa, G; Tung, N M; Pernas, S; Pare, L; Bueno-Muino, C;

  (...)

  Carey, L A; Mittendorf, E A; Martin, M; Prat, A; Tolaney, S M.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2023.

• Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab

  Autors:

  Waks, Adrienne G; Ogayo, Esther R; Pare, Laia; Marin-Aguilera, Mercedes; Braso-Maristany, Fara;

  (...)

  Perou, Charles M; Prat, Aleix; Winer, Eric P; Tolaney, Sara M; Mittendorf, Elizabeth A.

  Veure llistat complet d'autors

  Referència: Jama Oncology 2023.

• Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

  Autors:

  Prat, Aleix; Braso-Maristany, Fara; Martinez-Saez, Olga; Sanfeliu, Esther; Xia, Youli;

  (...)

  Gonzalez-Farre, Blanca; Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Vivancos, Ana.

  Veure llistat complet d'autors

  Referència: Nature Communications 2023.

• HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

  Autors:

  Braso-Maristany, Fara; Griguolo, Gaia; Chic, Nuria; Pascual, Tomas; Pare, Laia;

  (...)

  Parker, Joel S; Perou, Charles M; Conte, PierFranco; Prat, Aleix; Guarneri, Valentina.

  Veure llistat complet d'autors

  Referència: Journal Of The National Cancer Institute 2023.

• An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)

  Autors:

  Prat, A; Bardia, A; Curigliano, G; Viale, G; Hammond, MEH;

  Loibl, S; Tolaney, SM.

  Referència: Jama Oncology 2022.

• HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

  Autors:

  Guarneri, Valentina; Braso-Maristany, Fara; Vittoria Dieci, Maria; Griguolo, Gaia; Pare, Laia;

  (...)

  Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Conte, PierFranco; Prat, Aleix.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2022.

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;

  (...)

  Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2022.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Autors:

  Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

  (...)

  Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

  Veure llistat complet d'autors

  Referència: Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• Immune-related adverse events of checkpoint inhibitors

  Autors:

  Ramos-Casals, M; Flores-Chávez, A; Brahmer, JR; Callahan, MK; Keegan, N;

  Khamashta, MA; Lambotte, O; Marlette, X; Prat, A; Suarez-Almazor, ME.

  Referència: Nature Reviews Disease Primers 2020.

Projectes destacats

• Heterogeneidad intra-tumoral e impacto clínico en cáncer de mama precoz HER2-positivo y triple-negativo

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Instituto de Salud Carlos III

  Codi: PI22/01017

  Durada: 01/01/2023 - 31/12/2025

• A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

  Investigador/a principal: Jordi Rimola Gibert, Aleix Prat Aparicio

  Finançador: European Commission

  Codi: CE_H2020_SC1_20_1s13

  Durada: 01/10/2020 - 30/09/2024

• CRIS Research Excellence Programmes 2021. Dissecting and overcoming mechanisms of resistance to CDK4/6 inhibition in advanced hormone receptor-positive/HER2-Negative HER2-Enriched breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Codi: PR_EX_2021-14

  Durada: 01/07/2022 - 30/06/2027

• Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya.

  Investigador/a principal: Aleix Prat Aparicio, Joan Maurel Santasusana

  Codi: 2021-SGR-01156

  Durada: 01/01/2022 - 31/12/2024

• Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer.

  Investigador/a principal: Aleix Prat Aparicio

  Codi: 201935-30

  Durada: 30/07/2020 - 31/12/2023